Frank Hoentjen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Frank Hoentjen has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Bas Oldenburg
Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
4 shared publications Cyriel Ponsioen
4 shared publicationsDirk J. De Jong
4 shared publicationsStephen B. Hanauer
Inflammatory Bowel Disease Center, University of Chicago, Chicago, Illinois
4 shared publicationsAndrea Van Der Meulen
3 shared publicationsChristien Janneke Van Der Woude
3 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Sa1738 - Thiopurines Versus Anti-TNFα for the Prevention of Postoperative Recurrence in Crohn's Disease - A Metaanalsyis
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Sa1738 - Thiopurines Versus Anti-TNFα for the Prevention of Postoperative Recurrence in Crohn's Disease - A Metaanalsyis
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S587
Switching From Remicadeâ® to Biosimilar ct-P13 in Inflammatory Bowel Disease Patients: One Year Follow-Up of a Prospective Observational Cohort Study
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S587
Switching From Remicadeâ® to Biosimilar ct-P13 in Inflammatory Bowel Disease Patients: One Year Follow-Up of a Prospective Observational Cohort Study
- 1 April 2015
- Published by Elsevier in Gastroenterology
- Vol. 148 (4)
Mo1739 LPS Stimulated Whole Blood Cytokine Production and the Association With Disease Characteristics in Patients With Quiescent Crohn's Disease
- 1 April 2015
- Published by Elsevier in Gastroenterology
- Vol. 148 (4)
Mo1739 LPS Stimulated Whole Blood Cytokine Production and the Association With Disease Characteristics in Patients With Quiescent Crohn's Disease
- Open Access
- 1 April 2014
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. 7, 83-92
Management of Crohn's disease in poor responders to adalimumab
Anti-tumor necrosis factor therapy with adalimumab is an effective therapy for the induction and maintenance of remission in moderate to severe Crohn's disease. Although a large proportion of patients show a favorable clinical response to adalimumab, therapy failure is common. In this review, we provide a practical overview of adalimumab therapy in patients with Crohn's disease, with a specific focus on the clinical management of adalimumab failure. In the case of inadequate efficacy, a thorough assessment is required to confirm inflammatory disease activity and rule out noninflammatory causes. Evaluation may include biomarkers (fecal calprotectin and serum C-reactive protein), colonoscopy, and/or magnetic resonance enterography/enteroclysis. Furthermore, adalimumab trough levels and antibodies to adalimumab are informational after the confirmation of active inflammation. In the case of low or undetectable adalimumab trough levels, dose escalation to 40 mg weekly is recommended, whereas high antibody titers or adverse events frequently require switching to an alternative anti-TNF agent such as infliximab. Active inflammation despite therapeutic adalimumab trough levels requires alternative strategies such as switching to drugs with a different mode of action or surgical intervention.
- 1 April 2014
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. 7, 83-92
Open AccessManagement of Crohn's disease in poor responders to adalimumab
Anti-tumor necrosis factor therapy with adalimumab is an effective therapy for the induction and maintenance of remission in moderate to severe Crohn's disease. Although a large proportion of patients show a favorable clinical response to adalimumab, therapy failure is common. In this review, we provide a practical overview of adalimumab therapy in patients with Crohn's disease, with a specific focus on the clinical management of adalimumab failure. In the case of inadequate efficacy, a thorough assessment is required to confirm inflammatory disease activity and rule out noninflammatory causes. Evaluation may include biomarkers (fecal calprotectin and serum C-reactive protein), colonoscopy, and/or magnetic resonance enterography/enteroclysis. Furthermore, adalimumab trough levels and antibodies to adalimumab are informational after the confirmation of active inflammation. In the case of low or undetectable adalimumab trough levels, dose escalation to 40 mg weekly is recommended, whereas high antibody titers or adverse events frequently require switching to an alternative anti-TNF agent such as infliximab. Active inflammation despite therapeutic adalimumab trough levels requires alternative strategies such as switching to drugs with a different mode of action or surgical intervention.
- 1 March 2013
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (4) , 761-766
Elective Switching from Infliximab to Adalimumab in Stable Crohnʼs Disease
Background. Elective switching of biological therapy in patients with Crohn's disease (CD) in remission is generally discouraged, given the theoretical risk of
- 1 March 2013
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (4) , 761-766
Elective Switching from Infliximab to Adalimumab in Stable Crohnʼs Disease
Background. Elective switching of biological therapy in patients with Crohn's disease (CD) in remission is generally discouraged, given the theoretical risk of
- 1 February 2013
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (2) , 363-369
Safety and Effectiveness of Long-term Allopurinol–Thiopurine Maintenance Treatment in Inflammatory Bowel Disease
Background. Thiopurines are the mainstay of conventional maintenance therapy in inflammatory bowel disease (IBD). Unfortunately, up to 50% of patients disconti
- 1 February 2013
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (2) , 363-369
Safety and Effectiveness of Long-term Allopurinol–Thiopurine Maintenance Treatment in Inflammatory Bowel Disease
Background. Thiopurines are the mainstay of conventional maintenance therapy in inflammatory bowel disease (IBD). Unfortunately, up to 50% of patients disconti